EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Contract/Alliance
Berlin, Germany and BOCA RATON, FL, USA – 10 October 2023 – Eckert Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225 (Ac-225). Under the terms of the agreement, PharmaLogic will have access to Eckert Ziegler's high-purity, non-carrier-added Actinium-225 for the labeling of radiopharmaceuticals for research and development work and commercial use. Actinium-225 is used as an active substance in cancer treatment. The radioisotope emits powerful, high-energy alpha particles with short penetration depths, enabling precise treatment of tumor cells, including elusive micro-metastases, with minimal impact on surrounding healthy tissue. Clinical and market experts expect the demand of Actinium-225 to increase significantly over the next decade. "The supply of Actinium-225 has been limited for years, slowing both clinical research activities and commercial use,” stated Dr. Harald Hasselmann, CEO of Eckert Ziegler. “We have taken steps to improve this with the establishment of our own Ac-225 production facilities and are pleased to now support PharmaLogic’s activities to expand the use of Ac-225 based radiopharmaceuticals.” "Consistent with our mission to bring transformative radiopharmaceuticals to patients, increased access to key radioisotope Ac-225 is crucial for our organization and pharmaceutical partners,” explained Steve Chilinski, CEO of PharmaLogic. "Our agreement with Eckert Ziegler will ensure our programs can progress efficiently and enable patient access to the latest therapies.” Eckert Ziegler will establish GMP-compliant production of larger quantities of Ac-225 in 2024. Subsequently, the submission of a Drug Master File to the United States Food Drug Administration is planned. About Eckert Ziegler. About PharmaLogic Contact PharmaLogic Holdings Corporation
10.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1744641 |
End of News | EQS News Service |
|
1744641 10.10.2023 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie wird von der Community stark bevorzugt: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Die Community sieht für Eckert & Ziegler Strahlen- und Medizintechnik AG ein Kursziel von 95 €, was den aktuellen Kurs von 40.76 € weit übersteigt.